Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Efficacy predictors of a 2-month exclusive enteral nutrition for inducing remission of active Crohn’s disease

European Journal of Clinical Nutrition volume 72, pages 1183–1186 (2018)Cite this article

Subjects

Abstract

In order to identify the factors that could predict the efficacy of exclusive enteral nutrition (EEN) in inducing remission of active CD. Baseline clinical and laboratory covariates were correlated with the outcome (clinical remission) of EEN in active CD (CDAI ≥150) by both univariable and multivariable analyses. A total of 67 from a consecutive of 136 active CD patients were enrolled. L4b (from treitz ligament to distal 1/3 ileum) involvement was negatively and high serum albumin (≥35 g/L) was positively associated with clinical remission (OR: 0.14, OR: 14.71). In conclusion, L4b sparing and high serum albumin might predict a favorable outcome of EEN in active CD (ClinicalTrials.gov ID: NCT 02942511).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.

    Article  Google Scholar 

  2. Lau C, Dubinsky M, Melmed G, Vasiliauskas E, Berel D, McGovern D, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487–96.

    Article  Google Scholar 

  3. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.

    Article  Google Scholar 

  4. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744–53.

    Article  Google Scholar 

  5. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J Gastroenterol. 2013;19:7652–60.

    Article  Google Scholar 

  6. Hyams JS. Standardized recording of parameters related to the natural history of inflammatory bowel disease: from Montreal to Paris. Dig Dis. 2014;32:337–44.

    Article  Google Scholar 

  7. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut. 1996;38:543–8.

    Article  CAS  Google Scholar 

  8. Guo Z,Zhu W,Gong J,Zhang W,Wang Z,Li N, et al. Effects of exclusive enteral nutrition on the mucosal healing in adult patients with active Crohn’s Disease. Chin J Dig Dis. 2013;33:831–4.

    Google Scholar 

  9. Ruuska T, Savilahti E, Mäki M, Ormälä T, Visakorpi JK. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 1994;19:175–80.

    Article  CAS  Google Scholar 

  10. Datta G, Gnanalingham KK, van Dellen J, O’Neill K. The role of parenteral nutrition as a supplement to enteral nutrition in patients with severe brain injury. Br J Neurosurg. 2003;17:432–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Natural Science Foundation of Zhejiang Province (LQ17H160010), Zhejiang Provincial Medical and Health Research Project (2015104960), and National Natural Science Foundation of China (81702308, 81700455).

Author information

Author notes

    Authors and Affiliations

    1. Center for Inflammatory Bowel Diseases, Department of Gastroenterology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

      Meng Xue, Hanyun Zhang, Xiaoying Wang, Dingting Xu, Dan Jin, Peiwei Li, Jun Ye, Qiao Yu & Yan Chen

    2. Institute of Gastroenterology, Zhejiang University, Hangzhou, Zhejiang, China

      Meng Xue

    Authors
    1. Meng Xue
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Hanyun Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xiaoying Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Dingting Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Dan Jin
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Peiwei Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Jun Ye
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Qiao Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Yan Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Yan Chen.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    These two authors contributed equally: Meng Xue, Hanyun Zhang.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Xue, M., Zhang, H., Wang, X. et al. Efficacy predictors of a 2-month exclusive enteral nutrition for inducing remission of active Crohn’s disease. Eur J Clin Nutr 72, 1183–1186 (2018). https://doi.org/10.1038/s41430-018-0198-7

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1038/s41430-018-0198-7

    Search

    Advanced search

    Quick links